Patent · US Active

Combination containing sGC stimulators and mineralocorticoid receptor antagonists

US11684621B2 · kind B2 · utility

0Cited by

1References

25Claims

0Family size

Assignee

Bayer Pharma Aktiengesellschaft · DE

Inventors

Peter Kolkhof · Wuppertal, DE
Peter Sandner · Wuppertal, DE

Key dates

Filing date	Dec 31, 2020
Grant date	Jun 27, 2023
Priority date	—
Expiry date	Aug 8, 2041

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K45/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to the combination of stimulators of soluble guanylate cyclase (sGC stimulators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination for the treatment and/or prophylaxis of cardiac and cardiovascular disorders, of renal and cardiorenal disorders, of pulmonary and cardiopulmonary disorders and also for the treatment and/or prophylaxis of fibrotic disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.